Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The clinical profile of systemic sclerosis without a 'scleroderma pattern' at nailfold capillaroscopy: results from the multicenter SPRING registry of the Italian Society of Rheumatology.

Journal of translational autoimmunity·2026

Same author

Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort.

Arthritis care & research·2026

Same author

Combined immunosuppressive therapy in systemic sclerosis-associated interstitial lung disease: Phenotypes matter.

Autoimmunity reviews·2026

Same author

Clinical and serological features of triple autoantibody-negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for Rheumatology.

RMD open·2026

Same author

Real-world treatment patterns for metastatic urothelial cancer in 5 European countries: EVEREST 2.

Future oncology (London, England)·2026

Same author

Modulation of proinflammatory but not regulatory cytokines by in vitro JAK inhibition in peripheral blood B-cells of patients with psoriatic arthritis.

Journal of dermatological science·2026

Same journal

Pediatric andrology: bridging pediatric urology and reproductive medicine.

Current opinion in urology·2026

Same journal

Current impact of simulation-based surgical training in urology: a review from the European School of Urology and the European Association of Urology Endourology Section.

Current opinion in urology·2026

Same journal

Personalized therapy in metastatic hormone-sensitive prostate cancer: a 2026 update on navigating therapeutic complexity.

Current opinion in urology·2026

Same journal

Role and relevance of genetic testing in patients with kidney stones: a review from EAU Section of Endourology.

Current opinion in urology·2026

Same journal

Advances in evaluating and delivering nontechnical skills training: The use of simulation, robotics, artificial intelligence and virtual reality.

Current opinion in urology·2026

Same journal

Educating for a sustainable future: faculty and student perspectives and a review of environmental sustainability in medical education - an EAU endourology study.

Current opinion in urology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Second-line therapy in bladder cancer.

Mark Bachner¹, Maria De Santis

¹3rd Medical Department - Center for Oncology and Hematology, Kaiser Franz Josef-Spital der Stadt Wien, Ludwig Boltzmann Institute for Applied Cancer Research Vienna (LBI-ACR VIEnna), Vienna, Austria.

Current Opinion in Urology

|June 25, 2009

Summary

This summary is machine-generated.

Vinflunine shows promise as a new standard for second-line transitional cell carcinoma treatment. Clinical trials remain the best option for patients progressing after initial chemotherapy.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Experiment Videos

Last Updated: Jun 22, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Area of Science:

Oncology
Urothelial Carcinomas
Chemotherapy

Background:

Transitional cell carcinoma (TCC) of the urinary bladder lacks established second-line therapies.
Identifying prognostic and predictive factors is crucial for tailoring treatment intensity.
Current single-agent chemotherapy offers limited efficacy in pretreated patients.

Purpose of the Study:

To review recent advancements in second-line treatment for transitional cell carcinoma.
Focus on developments and findings from the past year.
Evaluate new therapeutic strategies and their outcomes.

Main Methods:

Review of recent clinical trials and retrospective studies.
Analysis of data on single-agent and combination chemotherapy.
Assessment of novel agents and treatment approaches.

Main Results:

Vinflunine demonstrated a modest but significant benefit with acceptable toxicity in a Phase III trial.
Single-agent chemotherapy yielded low response rates and survival.
Combination chemotherapy shows higher response rates but poorly understood survival benefits.
New agents and metronomic chemotherapy are under investigation.

Conclusions:

Vinflunine represents a potential new standard for second-line TCC treatment.
Treatment within clinical trials is recommended for patients progressing after first-line therapy.
Further research is needed to understand the role of combination chemotherapy and novel agents.